Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Relationship between autoimmunity and immunodeficiency in CLL

F Caligaris-Cappio1

  • 1Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Italy.

Hematology and Cell Therapy
|February 21, 1998
PubMed
Summary

Chronic lymphocytic leukemia (CLL) involves autoimmune issues and immunodeficiency. Activating CD40 on CLL cells may restore their antigen-presenting function, potentially aiding normal antibody production.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Leukemia·2017
Same author

B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia.

Leukemia·2016
Same author

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions.

Leukemia·2012
Same author

The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia.

Leukemia·2011
Same author

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Lancet (London, England)·2010

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • B-cell chronic lymphocytic leukemia (B-CLL) patients exhibit frequent autoimmune phenomena and hypogammaglobulinemia.
  • These conditions are linked to B-CLL's biological characteristics and cellular origins, particularly B-cell receptor abnormalities and microenvironmental influences.

Framework:

  • Focuses on defective CD79b expression, impacting B-cell receptor signaling and antigen presentation.
  • Explores the role of microenvironmental interactions, including cytokines and cell-cell contacts, in B-CLL progression.
  • Investigates the contribution of anergic, self-reactive CD5+ B lymphocytes to autoimmunity and immune incompetence.

Implementation:

  • CD5+ malignant B cells are inefficient antigen-presenting cells (APCs), hindering normal antibody production.
  • In vitro stimulation of the CD40 molecule on CLL cells with CD40 ligand converts them into efficient APCs.

Implications:

  • In vivo CD40 activation, potentially in the spleen, could enhance APC function in B-CLL.
  • This activation may promote polyclonal autoantibody production by normal B cells against self-antigens.
  • Understanding these mechanisms offers insights into managing autoimmunity and immunodeficiency in B-CLL.

Related Experiment Videos